An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and nebivolol or Paroxetine in healthy volunteers
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Inje University Busan Paik Hospital
Busan, South Korea
Cmax of Nebivolol
Cmax of Nebivolol
Time frame: Day 1, Day 2, Day 3, Day 6, Day 7, and Day 8
AUCt of Nebivolol
AUCt of Nebivolol
Time frame: Day 1, Day 2, Day 3, Day 6, Day 7, and Day 8
Cmax of DWN12088
Cmax of DWN12088
Time frame: Day 1, Day 2, Day 3, Day 4, Day 9, Day 10, Day 11, and Day 12
AUCt of DWN12088
AUCt of DWN12088
Time frame: Day 1, Day 2, Day 3, Day 4, Day 9, Day 10, Day 11, and Day 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.